Gene:
STK11
serine/threonine kinase 11

On ACMG incidental findings list

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  polarization-related protein LKB1
Alternate Symbols:  LKB1; PJS
PharmGKB Accession Id: PA36198

Details

Cytogenetic Location: chr19 : p13.3 - p13.3
GP mRNA Boundary: chr19 : 1205798 - 1228434
GP Gene Boundary: chr19 : 1195798 - 1231434
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

External Pathways

Links to non-PharmGKB pathways.

  1. Activated AMPK stimulates fatty-acid oxidation in muscle - (Reactome via Pathway Interaction Database)
  2. AMPK inhibits chREBP transcriptional activation activity - (Reactome via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Peutz-Jeghers Syndrome

Publications related to STK11: 6

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of solute carrier transporters in pancreatic cancer: a review. Pharmacogenomics. 2014. Lemstrov√° Radmila, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in medicine : official journal of the American College of Medical Genetics. 2013. Green Robert C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics. 2010. Metzger Ralf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature reviews. Cancer. 2009. Shackelford David B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Is pharmacogenomics our future? Metformin, ovulation and polymorphism of the STK11 gene in polycystic ovary syndrome. Pharmacogenomics. 2008. Goldenberg Naila, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. The Journal of clinical endocrinology and metabolism. 2008. Legro Richard S, et al. PubMed

LinkOuts

Entrez Gene:
6794
OMIM:
175200
273300
602216
UCSC Genome Browser:
NM_000455
RefSeq RNA:
NM_000455
RefSeq Protein:
NP_000446
RefSeq DNA:
AC_000062
AC_000151
NC_000019
NG_007460
NT_011255
NW_001838476
NW_927173
UniProtKB:
STK11_HUMAN (Q15831)
Ensembl:
ENSG00000118046
GenAtlas:
STK11
GeneCard:
STK11
MutDB:
STK11
ALFRED:
LO177364C
HuGE:
STK11
Comparative Toxicogenomics Database:
6794
ModBase:
Q15831
HumanCyc Gene:
HS04187
HGNC:
11389

Common Searches